David Haex

For the past twenty years, David has been supporting innovative companies in Belgium on their M&A and financing transactions as they search for transformation and growth opportunities. During this time, he has seen his clients grow from initial venture capital backed start-ups into Euronext-listed companies and even Nasdaq successes.

With almost 20 years of extensive sector experience, David specialises in every aspect of corporate transactional and finance work, such as public and private M&A, venture capital transactions, acquisition finance and general corporate lending, public offerings and (international) corporate restructurings. He has been consistently recommended in the legal directories for corporate M&A, where the corporate team is described as “without hesitation: excellent” and David himself being noted for “excelling at creating efficient solutions to complex problems”. 

David and his team work with some of the biggest technology and pharma companies and investors in the market. These include BioSenic, TiGenix, Infosys, Clarivate, Gilde Healthcare, Novo Nordisk and The Adecco Group. Work highlights include advising TiGenix on its NASDAQ IPO and subsequent €520 million sale to Takeda, advising Clarivate on its acquisition of darts-IP, advising BioSenic on various placements of shares and convertible bonds with European and U.S. investors and advising The Adecco Group on various acquisitions and investments in Belgium.

David joined Osborne Clarke as a Partner in 2013. He obtained his law degree from the KU Leuven (2001) and an LL.M at King’s College London (2003). In January 2021, David took over as Managing Partner of the Brussels office where he continues to head the Corporate practice.

David regularly contributes articles and commentaries on company law to the leading Belgian legal journal Revue de Droit Commercial Belge/Tijdschrift voor Belgisch Handelsrecht.